More? HIV Medicine 2007, Chapter 23: Download

HIV Medicine
15th edition
818 pages
PDF, 3.7 MB

Prevention Prevention is crucial, as the occurrence of cardiovascular disease is strongly related to lifestyles and modifiable risk factors. It has been shown that HIV-infected patients exhibit a marked cardiovascular risk profile (Neumann 2003, 2004a, 2004b). Most notably, in some countries the cigarette consumption is two- to three-fold higher than in the non-HIV-infected population. Furthermore, an association between antiretroviral drugs and lipid concentrations, i.e. hypercholesterolemia and hypertriglyceridemia, has been reported (Stocker 1998, Sullivan 1997). These lipid alterations might jeopardize the benefits of antiretroviral therapy by increasing the risk of coronary disease (Grover 2005). Lipid alterations were first shown with protease inhibitors, but there is now evidence that some NRTIs and NNRTIs have an unfavorable effect on lipids too. In addition to hyperlipidemia, insulin resistance has also been described in association with PIs (Behrens 1999, Noor 2001). However, new PIs such as atazanavir have a considerably more favorable lipid profile. Other authors presume an effect of virus antigens on the development of atherosclerosis (Hsue 2007), Prevention of coronary heart disease is based on the guidelines for non-HIV-infected patients (De Backer 2003; Table 1). Cessation of smoking and healthy food choices are the first steps in the therapy of hypercholesterolemia. The consumption of fruits, vegetables, whole grain bread and low fat dairy products in an energy balanced diet should be encouraged. The second step relies on lipid lowering drugs (Dube 2003). Good results were observed using a combination of statin (atorvastatin 10 mg/d) and fibrate (gemfibrozil 600 mg bid) (Henry 1998). However, an increased risk of rhabdomyolysis is suspected, and thus caution is required. Table 1: Prevention of coronary heart disease 1) Cease Smoking 2) Make healthy food choices 3) Normalization of lipids a. LDL-Cholesterol: - low risk (0-1 risk factors): < 160 mg/dl (4.14 mmol/l) - intermediate risk (2 or more risk factors): < 130 mg/dl (3.36 mmol/l) - high risk (i.e. CHD or diabetes mellitus): < 100 mg/dl (2.59 mmol/l) b. HDL-Cholesterol: > 35 mg/dl (0.90 mmol/l) (increased risk > 40 mg/dl) c. Triglycerides: < 200 mg/dl (5.17 mmol/l) (increases risk < 150 mg/dl) 4) Optimize blood glucose value (HbA1c < 6.5 %) 5) Reduce alcohol consumption (< 15 g/d) 6) Regular exercise training (1-2 h per week) 7) Normalization of weight (BMI of 21-25 kg/m²) 8) Optimize blood pressure (systolic: < 130 mmHg, diastolic < 85 mmHg) Furthermore, statin therapy might interact with the metabolism of common antiretroviral drugs. In particular, several PIs act as substrates for isoenzyme 3A4, a subgroup of the cytochrome p450 system. Inhibition of isoenzyme 3A4 by antiretroviral drugs can increase the blood concentration of statins and, therefore, induce side effects (Dube 2000). In contrast to most other statins, pravastatin and fluvastatin are not modulated by isoenzyme 3A4. Therefore, these two drugs are preferred by some authors for the therapy of HIV-infected patients being treated with antiretroviral drugs. Diagnosis HIV-infected patients with cardiovascular risk factors or of elevated age should undergo an annual cardiac check-up, including a resting ECG and estimation of the cardiovascular disease risk with the help of the SCORE system (De Backer 2003). The time between two cardiac controls should be shortened in case of high cardiovascular risks. Symptomatic patients also need further detailed cardiovascular examinations (exercise ECG, stress echocardiography, laboratory work-up and, in some cases, scintigraphy of myocardium or coronary angiography). Clinical symptoms of coronary heart disease mostly occur due to a critical stenosis of more than 75 %. Therefore, the onset of new cardiac symptoms or an increase in gravity, duration or frequency, referred to as acute coronary syndrome, needs direct and immediate clarification (Erhardt 2002). Therapy In randomized clinical trials, low-dose aspirin (100 mg/d), or in some cases clopidogrel (75 mg/d), ß-blockers, ACE inhibitors, and statins, decreased the risk of mortality and re-infarction. A calcium antagonist and/or nitrate can be supplemented for symptomatic treatment. The indication for vascular intervention (coronary angiography, including percutaneous transluminal catheter angioplasty and stent implantation) depends on the current guidelines (see http://www.escardio.org/knowledge/guidelines). Clear indications for invasive diagnosis are a documented exercise-induced ischemia, typical clinical symptoms together with ST-alterations in the ECG, increases in cardiac enzymes and/or a marked cardiovascular risk profile. It is worth emphasizing that HIV infection is not an exclusion criteria for invasive procedures. Successful cardiac interventions have been performed on HIV-infected patients, including catheter procedures and coronary artery bypass operations (Escaut 2003, Bittner 2003, Ambrose 2003). Congestive heart failure Congestive heart failure includes a variety of myocardial alterations. In HIV-infected patients, the HIV-associated dilated cardiomyopathy is of major interest and a significant clinical problem in HIV-infected patients (Twagirumukiza 2007). Etiology Myocarditis is still the most thoroughly studied cause of dilated cardiomyopathy in HIV disease. Until now, a variety of pathogens has been found in the myocardial tissue of HIV-infected patients (Patel 1996, Wu 1992). Furthermore, human immunodeficiency virus itself appears to infect myocardial cells in a patchy distribution. Although it is unclear how HIV-1 enters CD4-receptor-negative cells such as cardiomyocytes, reservoir cells may play a role in the interaction between HIV-1 and myocytes. In addition to a direct impact of the human immunodeficiency virus or other pathogens, dilated cardiomyopathy was reported in association with an autoimmune reaction. Cardiac-specific autoantibodies (anti-a-myosin antibodies) have been reported in up to 30 % of HIV-infected patients with cardiomyopathy. However, several studies also indicate that in HIV-infected patients, dilated cardiomyopathy is associated with cardiotoxic agents (e.g. pentamidine, interleukin-2, doxorubicin), cytokines (Monsuez 2007) or as the sequelae of malnutrition (Nosanchuk 2002). Furthermore, it is expected that antiretroviral therapeutic drugs may induce cardiac dysfunction due to mitochondrial toxicity (Lewis 2000, Frerichs 2002). The frequency of clinical, symptomatic dilated cardiomyopathy is estimated to be between 1 and 5 %. However,in one study, only 30 % of HIV-infected individuals with ventricular malfunction could be identified by characteristic clinical symptoms (Roy 1999). In African countries, HIV-associated cardiomyopathy is a significant clinical problem in up to 18% (Twagirumukiza 2007). Thus, reliance on clinical features of heart failure only, will fail to identify patients who might benefit from treatment. Diagnosis The diagnosis of chronic heart failure is based on clinical findings and symptoms. In addition to exercise intolerance, patients often exhibit dyspnea and edema. Nocturia, nightly cough (cardiac asthma), peripheral cyanosis and an increase of weight may also occur. In these cases, ECG, chest x-ray and echocardiography may lead to the diagnosis of heart failure. A new parameter in the diagnosis of heart failure is the b-type natriuretic peptide (BNP) or NTproBNP. This peptide has the power to distinguish between lung and cardiac malfunction. Exercise intolerance can be determined by a 6-minute walk test, exercise ECG or spiroergometry. In some cases, further diagnosis can be performed with magnetic resonance tomography (MRT) or computer tomography (CT) revealing information about etiology and type of cardiomyopathy (Breuckmann 2007). Invasive diagnosis including myocardial biopsies is often recommended in unknown cases of chronic heart failure. Stable chronic heart failure patients in a low stage should be controlled annually. In a higher stage, the controls should include ECG, echocardiography and occasional BNP measurements every 6 months. Therapy The therapy of congestive heart failure depends on current guidelines (www.escardio.org/knowledge/ guidelines) and begins with moderate and regular exercise in combination with a healthy diet, including a reduced fluid and salt intake. Non-steroidal anti-rheumatics (NSAR), class I antiarrhythmics and calcium antagonists (verapamil, diltiazem and short-acting dihydropyridine derivates) should be used carefully. Treatment of congestive heart failure includes: § from NYHA I (asymptomatic heart failure): ACE inhibitor or AT1-antagonists (control blood pressure and renal function) beta-blocker for patients after myocardial infarction (beginning with low dose therapy under regular control of blood pressure and heart rate. If a low-dose therapy is tolerated, the beta-blocker medication should be increased slowly). § from NYHA II (slight limitation of physical activity): beta-blockers for all patients, digitalis glycosides and diuretics. § from NYHA III (marked limitation of physical activity): spironolactone (low dose with controlled potassium). § from NYHA IV (unable to carry out any physical activity) reinforce medical treatment (combination of diuretics), consider heart transplantation (Jahangiri 2007), reconsider any surgical improvement and device implantation NYHA III and NYHA IV require cooperation with a cardiologist. In the presence of ventricular arrhythmia, the indications for an implantable cardioverter defibrillator (ICD) have to be considered. Therapeutic options that could eliminate the causes of heart failure (such as operative valve replacement in the case of a primary vitium or intensive antibiotic therapy for bacterial myocarditis) have priority. In these cases, cooperation with a specialized center is recommended. Prognosis Chronic heart failure is associated with a reduced life expectancy. In cases of NYHA III-IV, the annual mortality rate rises by up to 30 %. While in some cases, a total recovery was described (Fingerhood 2001, Tayal 2001), the majority of patients with HIV-associated dilated cardiomyopathy still have a progression of left ventricular dysfunction (Felker 2000). It is still unclear whether antiretroviral medication has an influence on the recovery of ventricular function. Early diagnosis and conventional therapy seem to be the most promising ways to reduce the progression of disease. Pericardial effusion Before effective antiretroviral drugs were available, pericardial effusion was the most frequent cardiac manifestation. In clinical trials, the incidence of pericardial effusions was recognized to be as high as 11 % per year (Heidenreich 1995). However, the majority of HIV-associated pericardial manifestations are described as asymptomatic. Nevertheless, the spectrum ranges from acute or chronic pericarditis to an acute pericardial tamponade (Silva-Cardoso 1999) and may result in constrictive pericarditis (Sa 2006). Pericardial diseases could be caused by HIV itself, further pathogens, or neoplasms (Stotka 1989). In a recent report from South Africa, where pericardial effusion is obviously still more common than in Europe or North America, 96 % of HIV patients with large pericardial effusions had tuberculous pericarditis (Reuter 2005). However, non-HIV-associated causes of pericardial effusion, such as uremia, trauma, irradiation, and drugs, have to be considered. In some cases of lipodystrophy an increase in the cardiac lipid tissue could simulate an extensive pericardial effusion (Neumann 2002c). Echocardiography is referred to as the standard method for diagnosis and control of pericardial diseases. Nevertheless, further diagnosis should be performed by computer tomography and/or magnetic resonance tomography when a neoplasm or an increase in the cardiac lipid tissue is suspected. Pericardial puncture has to be considered for symptomatic patients. If possible, a causative therapy should be applied. Pericardiotomy might be an option in palliative care. Cardiac arrhythmias Cardiac arrhythmias can depend on medication (Anson 2005). Antiretroviral drugs, e.g. atazanavir, efavirenz, foscarnet, pentamidine, or co-therapy with methadone, are expected to prolong the QT interval, an alteration in ECG, which might cause "Torsade de pointes" tachycardia (Castillo 2002, Chinello 2007, Ly 2007). Further drug combinations such as a macrolide and a chinolone may have the same effect on the QT interval. Initiation or change of medication, which might influence the QT interval, should be controlled daily by ECG. In case of arrhythmias, electrolyte and glucose concentrations have to be determined and corrected if necessary. Magnesium may be used for termination of torsades de pointes tachycardia. Valvular heart disease Valvular heart disease of HIV-infected patients occurs as a bacterial or mycotic endocarditis. In fact, the hypothesis that HIV infection alone makes a subject more susceptible to infective endocarditis could not be validated. However, intravenous drug abusers have a ten- to twelve-fold increased risk for infective endocarditis than non-intravenous drug abusers (Nahass 1990). The most frequent germ is staphylococcus aureus, being detected in more than 40 % of HIV-infected patients with bacterial endocarditis. Further pathogens include Streptococcus pneumoniae and Hemophilus influenzae (Currie 1995). Mycotic forms of endocarditis, which may also occur in patients who are not intravenous drug abusers, mostly belong to Aspergillus fumigatus, Candida species or Cryptococcus neoformans and are associated with a worse outcome (Martin-Davila 2005). Even if non-drug-abusing HIV patients are not more susceptible to infective endocarditis, the clinical course of the infection is more severe and the outcome worse than in a non-HIV-infected population (Smith 2004). Signs of infective endocarditis include fever (90 %), fatigue, and lack of appetite. An additional heart murmur may also be present (30 %). In these cases, repeated blood cultures should be taken and transesophageal echocardiography is mandatory (Bayer 1998). Due to the fact that the detection of the infectious agent is often difficult, an antibiotic therapy has to be started early, even without the microbiology results. In most cases, previously damaged valves are affected. Therefore, antibiotic prophylaxis is recommended in all persons with a previously damaged endocardium and planned interventional procedure, e.g. dental work or operations on the respiratory or gastrointestinal tract. For diagnosis, antibiotic prophylaxis, and choice and length of antibiotic treatment, please refer to your local cardiologist and to the European guidelines for infective endocarditis (http://www.escardio.org/knowledge/guidelines/). Further cardiac manifestations Heart neoplasms are rarely found in HIV-infected patients. These manifestations occur predominantly in the advanced stages of the disease. On autopsy, the rates of cardiac-localized Kaposi's sarcoma and lymphoma are less than one percent. Some infections of the heart in HIV-positive subjects may not only result in myocarditis but in abscesses. Several opportunistic pathogens including toxoplasma and trypanosomes have been reported to causes abscesses in the heart. These manifestations are believed to decrease with the introduction of HAART. As well as neoplasms and abscesses, vascular alterations including vasculitis and perivasculitis have been described as further cardiovascular manifestations in HIV-infected patients. In particular, the function of the pulmonary vessels can deteriorate, resulting in pulmonary arterial hypertension and, consequently, right heart failure (Mehta 2000). For further information on pulmonary arterial hypertension see the chapter "HIV-associated pulmonary hypertension (PAH)". Table 2. Cardiac diseases in HIV-infected patients Pericardial diseases § Pericardial effusion § Pericarditis (viral, bacterial, mycotic) § Neoplasm (Kaposi's sarcoma, lymphoma) Myocardial diseases § HIV-associated dilated cardiomyopathy § Myocarditis (acute or chronic) § Neoplasm (Kaposi's sarcoma, lymphoma) § Drug side-effects (especially by antiretroviral therapy) Endocardial diseases § Infective endocarditis (bacterial, mycotic) § Nonbacterial thrombotic endocarditis Vascular diseases § Atherosclerosis § Vasculitis, perivasculitis § Pulmonary arterial hypertension Creation of the present chapter is supported by the German Heart Failure Network (www.knhi.de). References 1. Anson BD, Weaver JG, Ackerman MJ, et al. Blockade of HERG channels by HIV protease inhibitors. Lancet. 2005;365:682-6 http://amedeo.com/lit.php?id=15721475 2. Bayer AS, Bolger AF, Taubert KA et at. Diagnosis and management of infective endocarditis and its complications. Circulation 1998; 98: 2946-48. http://amedeo.com/lit.php?id=9860802 3. Behrens G, Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999, 13: F63-70. http://amedeo.com/lit.php?id=10416516 4. Bittner HB, Fogelson BG. Off-pump coronary artery bypass grafting in a patient with AIDS, acute myocardial infarction, and severe left main coronary artery disease. J Cardiovasc Surg 2003; 44: 55-7. http://amedeo.com/lit.php?id=12627072 5. Breuckmann F, Nassenstein K, Kondratieva J, et al. German Heart Failure Network; Competence Network HIV/AIDS.MR characterization of cardiac abnormalities in HIV+ individuals with increased BNP levels.Eur J Med Res. 2007;12:185-90. http://amedeo.com/lit.php?id=17513188 6. Castillo R, Pedalino RP, El-Sherif N, Turitto G. Efavirenz-assoziated QT prolongation and Torsade de Pointes arrhythmia. Ann Pharmacother 2002, 26:1006-8. http://amedeo.com/lit.php?id=12022902 7. Chinello P, Lisena FP, Angeletti C, Boumis E, Papetti F, Petrosillo N. Role of antiretroviral treatment in prolonging QTc interval in HIV-positive patients. J Infect. 2007;54:597-602. http://amedeo.com/lit.php?id=17443482 8. Currie PF, Sutherland GR, Jacob AJ, et al. A review of endocarditis in acquired immunodeficiency syndrome and human immunodeficiency virus infection. Eur Heart J 1995; 16: 15-8. http://amedeo.com/lit.php?id=7671917 9. Dakin CL, OŽConnor CA, Patsdaughter CA. HAART to heart: HIV-related cardiomyopathy and other cardiovascular complications. AACN Clin Issues 2006; 17:18-29 http://amedeo.com/lit.php?id=16462405 10. Danesh J, Collins R, Peto R. Chronic infections and coronary artery disease: is there a link? Lancet 1997; 350: 430-6. http://amedeo.com/lit.php?id=9259669 11. De Giorgio F, Abbate A, Capelli A, Arena V. Spontaneous rupture of coronary artery in human immunodeficiency virus - positive patient treated with highly active anti-retroviral therapy (HAART). Am J Forensic Med Pahtol 2005; 26: 197. http://amedeo.com/lit.php?id=15894860 12. Dietz R, Rauch B. Leitlinien zur Diagnostik und Behandlung der chronischen koronaren Herzerkrankung der Deutschen Gesellschaft für Kardiologie - Herz- und Kreislaufforschung (DGK). Z Kardiol. 2003; 92: 501-21. http://amedeo.com/lit.php?id=12905980 13. Dosios TJ, Theakos NP, Angouras DC et al. AIDS-related cardiac tamponade: is surgical drainage justified? Ann Thorac Surg 2004; 78: 1084-5. http://amedeo.com/lit.php?id=15337059 14. Dube MP, Sprecher D, Henry WK, et al. Preliminary guidelines for the evaluation and management of dyslipidemia in adults infected with human immunodeficiency virus and receiving antiretroviral therapy: recommendations of the adult AIDS clinical trial group cardiovascular disease focus group. Clin Inf Dis 2000; 31: 1216-24. http://amedeo.com/lit.php?id=11073755 15. Dube MP, Stein JH, Aberg JA. Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy: recommendations of the HIV Medical Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group. Clin Infect Dis 2003; 37: 613-27. http://amedeo.com/lit.php?id=12942391 16. El-Sadr WM, Lundgren JD, Neaton JD (SMART-Study Group) CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006 Nov 30;355(22):2283-96 http://amedeo.com/lit.php?id=17135583 17. Felker GM, Thompson RE, Hare JM, et al. Underlying causes and long-term survival in patients with initially unexplained cardiomyopathy. N Engl J Med 2000, 342: 1077-84. http://amedeo.com/lit.php?id=10760308 18. Fiala M, Popik W, Qiao JH et al. HIV-1 induced cardiomyopathy by cardiomyocyte invasion and gp120, Tat, and cytokine apoptotic signaling. Cardiovasc Toxicol 2004; 4: 97-107. http://amedeo.com/lit.php?id=15371627 19. Fingerhood M. Full recovery from severe dilated cardiomyopathy in an HIV-infected patient. AIDS Read 2001; 11: 333-5. http://amedeo.com/lit.php?id=11449927 20. Frerichs FC, Dingemans KP, Brinkman K. Cardiomyopathy with mitochondrial damage associated with nucleoside reverse transcriptase inhibitors. N Eng J Med 2002; 347: 1895-6. http://amedeo.com/lit.php?id=12466522 21. Friis-Moller N, Sabin CA, Weber R et al. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003. http://amedeo.com/lit.php?id=14627784 22. Friis-Møller N, Reiss P, Sabin CA (DAD Study Group) et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med. 2007;356:1723-35. http://amadeo.com/lit.php?id=17460226 23. Glazier JJ, Spears JR, Murphy MC. Interventional approach to recurrent myocardial infarction in HIV-1 infection. J Interv Cardial 2006; 19:93-8. http://amedeo.com/lit.php?id=16483347 24. Gohlke H, Kübler W, Mathes P, et al. Positionspapier zur Primärprävention kardiovaskulärer Erkrankungen. Z Kardiol 2004; 93 Suppl 2:II43-5. http://amedeo.com/lit.php?id=15021996 25. Heidenreich PA, Eisenberg MJ, Kee LL, et al. Pericardial effusion in AIDS incidence and survival. Circualtion 1995; 92: 3229-34. http://amedeo.com/lit.php?id=7586308 26. Hoppe UC, Erdmann E. Leitlinien zur Therapie der chronischen Herzinsuffizienz. Z Kardiol. 2001; 90: 218-37. http://amedeo.com/lit.php?id=11315582 27. Hsue PY, Hunt PW, Sinclair E, et al. Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responses. AIDS. 2006;20:2275-83. http://amedeo.com/lit.php?id=17117013 28. Iwahashi N, Nakatani S, Kakuchi H, et al. Cardiac tumor as an initial manifestation of acquired immunodeficiency syndrome. Circ J 2005; 69: 243-5. http://amedeo.com/lit.php?id=15671621 29. Jahangiri B, Haddad H. Cardiac transplantation in HIV-positive patients: are we there yet? J Heart Lung Transplant. 2007;26:103-7. http://amedeo.com/lit.php?id=17258141 30. Khan NU, Ahmed S, Wagner P, et al. Cardiac involvement in non-HodgkinŽs lymphoma: with and without HIV infection. Int J Cardiovasc Imaging 2004; 20: 477-81. http://amedeo.com/lit.php?id=15856629 31. Kjaer A, Lebech AM, Gerstoft J, et al. Right ventricular volume and mass determined by cine magnetic resonance imaging in HIV patients with possible right ventricular dysfunction. Angiology 2006;57:341-6 http://amedeo.com/lit.php?id=16703194 32. Kovanen PT, Manttari M, Palosuo T, et al. Predictions of myocardial infarction in dislipidemic men by elevated levels of immunoglobulin classes A, E, and F, but not M. Arch Intern Med 1998; 158: 1434-9. http://amedeo.com/lit.php?id=9665352 33. Lanjewar DN, Agale SV, Chitale AR, Joshh SR. Sudden death due to cardiac toxoplasmosis. J Assoc Physicians India 2006;54:244-5 http://amedeo.com/lit.php?id=16800354 34. Law MG, Friis-Moller N, El-Sadr WM et al. The use of the Framingham equation to predict myocardial infarctions in HIV-infected patients: comparison with observed events in the D:A:D Study. HIV Med 2006;7:218-30 http://amedeo.com/lit.php?id=16630034 35. Letts DP, Lopez-Candales A. Atypical echocardiographic findings of endocarditis in an immunocompromised patient. Echocardiography 2004; 21: 715-9. http://amedeo.com/lit.php?id=15546372 36. Lewis W, Kohler JJ, Hosseini SH et al. Antiretroviral nucleosides, deoxynucleotide carrier and mitochondrial DNA: evidence supportino the DNA pol gamma hypothesis. AIDS 2006;20:675-84. http://amedeo.com/lit.php?id=16514297 37. Ly T, Ruiz ME. Prolonged QT interval and torsades de pointes associated with atazanavir therapy. Clin Infect Dis. 2007;44:e67-8. http://amedeo.com/lit.php?id=17304444 38. McKee EE, Bentley AT, Hatch M. Phophorylation of thymidine and AZT in heart mitochondria: elucidation of a novel mechanism of AZT cardiotoxicity. Cardiovasc Toxicol 2004; 4: 155-67. http://amedeo.com/lit.php?id=15371631 39. Mirza H, Patel P, Suresh K, Krukenkamp I, Lawson WE. HIV disease and an atherosclerotic ascending aortic aneurysm. Rev Cardiovasc Med. 2004; 5: 176-81. http://amedeo.com/lit.php?id=15346102 40. Monsuez JJ, Escaut L, Teicher E, et al. Cytokines in HIV-associated cardiomyopathy. Int J Cardiol. 2007;120:150-7. http://amedeo.com/lit.php?id=17336407 41. Neumann T, Ross B, Hengge UR, et al. Kardiale Manifestationen der HIV-Infektion. Med Klin 2002a; 97: 659-65. http://amedeo.com/lit.php?id=12434274 42. Neumann T, Miller M, Esser S, et al. Arteriosklerose bei HIV positiven Patienten. Z Kardiol 2002b; 91: 879-88. http://amedeo.com/lit.php?id=12442190 43. Neumann T, Canbay A, Barkhausen M, et al. Paracardial lipodystrophy versus pericardial effusion in HIV positive patients. Heart 2002c; 87: e4. http://amedeo.com/lit.php?id=11997434 44. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part I: Differences due to the acquisition of HIV-infection. Eur J Med Res 2003; 8: 229-35. http://amedeo.com/lit.php?id=12911871 45. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part II: Gender differences. Eur J Med Res 2004; 9: 55-60. http://amedeo.com/lit.php?id=15090290 46. Neumann T, Woiwod T, Neumann A, et al. Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part III: Age differences. Eur J Med Res 2004, 9: 267-72. http://amedeo.com/lit.php?id=15257881 47. Nosanchuk JD. Fungal myocarditis. Front Biosci 2002; 7: d1423-38. http://amedeo.com/lit.php?id=12045009 48. Obel N, Thomsen HF, Kronborg G, et al. Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis. 2007;44:1625-31. http://amedeo.com/lit.php?id= 17516408 49. Patel RC, Frishman WH. Cardiac involvement in HIV infection. Med Clin North Am 1996; 80: 1493-512. http://amedeo.com/lit.php?id=8941233 50. Paton P, Tabib A, Loire R, Tete R. Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993; 144: 225-31. http://amedeo.com/lit.php?id=8356344 51. Peter AA, Seecheran S. Images in cardiology: Multiple ventricular thrombus in HIV cardiomyopathy. Heart 2005; 91: 1248 http://amedeo.com/lit.php?id=16103578 52. Rangasetty UC, Rahman AM, Hussain N. Reversible right ventricular dysfunction in patients with HIV infection. South Med J 2006;99:274-8 http://amedeo.com/lit.php?id=16553101 53. Reuter H, Burgess LJ, Schneider J, et al. The role of histopathology in establishing the diagnosis of tuberculous pericardial effusions in the presence of HIV. Histopathology 2006; 48:295-302 http://amedeo.com/lit.php?id=16430476 54. Reuter H, Burgess LJ, Carstens ME, Doubell AF. Characterization of the immunological features of tuberculous pericardial effusions in HIV positive and HIV negative patients in contrast with non-tuberculous effusions. Tuberculosis 2006;86:125-33. http://amedeo.com/lit.php?id=16360340 55. Roy VP, Prabhakar S, Pulvirenti J, Mathew J. Frequency and factors associated with cardiomyopathy in patients with human immunodeficiency virus infection in an inner-city hospital. J Natl Med Assoc 1999; 91: 502-4. http://amedeo.com/lit.php?id=10517069 56. Sa I, Moco R, Cabral S, Reis AH, et al.Constrictive pericarditis of tuberculous etiology in the HIV-positive patient: case report and review of the literature. Rev Port Cardiol. 2006 Nov;25(11):1029-38. http://amedeo.com/lit.php?id=17274459 57. Saporito F, Micari A, Raffa S, et al. Acute myocardial infarction and rescue percutaneous transluminal coronary angioplasty in a young HIV - infected patient. Int J Clin Pract 2005; 59: 376-8. http://amedeo.com/lit.php?id=15857340 58. Silva-Cardoso J, Moura B, Martins L, et al. Pericardial involvement in human immunodeficiency virus infection. Chest 1999; 115: 418-22. http://amedeo.com/lit.php?id=10027441 59. Stocker DN, Meier PJ, Stoller R, Fattinger KE. "Buffalo hump" in HIV-1 infection. Lancet 1998; 352: 320-1. http://amedeo.com/lit.php?id=9690434 60. Stotka JL, Good CB, Downer WR, et al. Pericardial effusion and tamponade due to Kaposi`s sarcoma in acquired immunodeficiency syndrome. Chest 1989; 95: 1359-61. http://amedeo.com/lit.php?id=2721281 61. Sullivan AK, Nelson MR. Marked hyperlipidaemia on ritonavir therapy. AIDS 1997; 11: 938-9. http://amedeo.com/lit.php?id=9189227 62. Tayal SC, Ghosh SK, Reaich D. Asymptomatic HIV patient with cardiomyopathy and nephropathy: case report and literature review. J Infect 2001; 42: 288-90. http://amedeo.com/lit.php?id=11545577 63. Twagirumukiza M, Nkeramihigo E, Seminega B, et al. Prevalence of dilated cardiomyopathy in HIV-infected African patients not receiving HAART: a multicenter, observational, prospective, cohort study in Rwanda. Curr HIV Res. 2007 Jan;5(1):129-37. http://amedeo.com/lit.php?id=17266564 64. Umeh OC, Currier JS. Lipids, metabolic syndrome, and risk factors for future cardiovascular disease among HIV-infected patients. Curr HIV/AIDS Rep 2005; 2:132-9. http://amedeo.com/lit.php?id=16091260 65. Wu TC, Pizzorno MC, Hayward GS, et al. In situ detection of human cytomegalovirus immediate-early gene transcripts within cardiac myocytes of patients with HIV-associated cardiomyopathy. AIDS 1992; 6: 777-85. http://amedeo.com/lit.php?id=1329847